Business
AI suggests Australia may have backed a COVID-19 vaccine winner – The Australian Financial Review
Even the COVID-19 vaccines in phase three clinical trials have only a 20 per cent chance of success, an Australian AI healthcare data company says.
Some of the positive factors supporting the vaccine were the number of trial locations (approximately 20), trial participants (more than 12,000) and its randomised design. The chance of the trial succeeding could be improved by increasing the number of countries where the trial operates.
Ms Gallaher, who has spent 30 years in the biotech and pharmaceutical industry, and has also taken part in clinical trials, hoped the research would help governments and investors around the globe to pick which…
-
Business20 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
Noosa News15 hours agoRacing Queensland responds to criticism of ‘deadliest’ greyhound track
-
Noosa News23 hours agoDramatic details emerge of moment woman loses arm in attack by lion in Queensland Zoo
-
General19 hours agoTrump’s AUKUS review coming soon. Will he stop the folly?